Researchers identified and examined factors that contributed to the rising enrollments in the AIDS Drug Assistance Program (ADAP) from 2008 through 2011 and assessed states' abilities to meet the demands for ADAP services.
Case studies of eight programs provided insight into the challenges faced by ADAPs and how they differ by state. There is little evidence that waitlist states faced greater enrollment pressures than non-waitlist states whether measured by changes in unemployment, HIV/AIDS prevalence, Medicaid enrollment, private insurance coverage or SSI receipt. Waitlist states were not disadvantaged in ADAP funding through ADAP awards, Part B contributions or other State contributions when measured per enrollee. Non-waitlist states greatly increased rebate funding per enrollee starting in 2009, perhaps because their reliance on rebates through pharmacy networks better positioned them to receive supplemental rebates and rebates for partial payments for insured clients. Some strategies yielded cost savings through administrative efficiencies in non-waitlist states. States without waitlists were more likely to maximize the use of shared information systems for enrollment, prescription processing, and general administration than those with waitlists.
Report Title: Assessing Factors That Impact AIDS Drug Assistance Program (ADAP) Enrollment and Management in the Face of ADAP Waitlists
Agency Sponsor: HRSA, Health Resources and Services Administration
Federal Contact: Faye Malitz, 301-443-3259
Performer: Walter R. McDonald & Associates, Inc.
Record ID: 10211 (January 31, 2013)